Advertisement
News
Advertisement

AVEO Pharmaceuticals starts exploratory biomarker trial enrollment

Thu, 02/03/2011 - 4:35am
Mass High Tech: The Journal of New England Technology

Cambridge-based AVEO Pharmaceuticals Inc. (Nasdaq: AVEO) said it has started enrolling patients in a Phase 2 exploratory biological marker study of tivozanib, its lead treatment for renal cell carcinoma (RCC).

A primary goal is to evaluate biomarkers in blood and archived tissue samples and their correlation with tivozanib’s clinical activity and/or drug-related toxicity, according to the company. A biomarker can help tell how well the body responds to a treatment.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading